Storage
Powder: -20℃; In solvent: -80℃ for 1 year
Synonyms
Zemuron Esmeron Rocuronium (Bromide) ORG 9426
Molecular Formula
C32H53BrN2O4
Smiles
CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-]
Appearance
Off-white or light yellow powder
General Description
Rocuronium bromide is a fast-onset, intermediate-acting, non-depolarizing neuromuscular blocking agent (NMBA). It is a synthetic quaternary aminosteroid compound, chemically designated as an analogue of pancuronium and vecuronium. Rocuronium is characterized by its rapid onset of action, which is the fastest of any currently available non-depolarizing muscle relaxant, making it a clinically useful alternative to succinylcholine in certain rapid sequence intubation (RSI) scenarios.
Mechanism of Action
Rocuronium produces its muscle relaxant effect by acting as a competitive antagonist at nicotinic cholinergic receptors located on the motor end-plate of skeletal muscle.
Application
Rocuronium bromide is indicated as an adjunct to general anesthesia to facilitate both routine and rapid sequence tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures or mechanical ventilation in the intensive care unit (ICU).
Baek et al. reported that rocuronium bromide exerts differential regulatory effects on vascular endothelial cells, as demonstrated in cultured CPAE cells. Rocuronium bromide treatment suppressed endothelial nitric oxide synthase (eNOS) activity, leading to reduced nitric oxide (NO) production. Concurrently, the compound activated cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). This activation resulted in increased synthesis of prostaglandin E2 (PGE2).
Fig. 1 The effects of rocuronium bromide treatment on cyclooxygenase-1 (COX-1) in calf pulmonary artery endothelial (CPAE) cells. (Baek SB, et al., 2016)
References
- Baek SB, et al. Rocuronium Bromide Inhibits Inflammation and Pain by Suppressing Nitric Oxide Production and Enhancing Prostaglandin E2 Synthesis in Endothelial Cells. Int Neurourol J. 2016, 20(4):296-303.
Chompunud Na Ayudhya C, et al. demonstrated that rocuronium directly activates mast cell degranulation through distinct receptor pathways in mice and humans, providing the first evidence of MRGPRX2-mediated activation in human mast cells. In mouse peritoneal mast cells (PMCs), rocuronium (20 µg/mL) induced degranulation via MrgprB2, the murine ortholog of the human MRGPRX2 receptor. In human mast cells, degranulation required a higher concentration (≥500 µg/mL) and was mediated specifically through MRGPRX2. This study provides the first direct evidence that rocuronium induces degranulation in human mast cells through engagement of MRGPRX2.
Fig. 2 Rocuronium activates mouse peritoneal mast cells (PMCs) via MrgprB2. (Chompunud Na Ayudhya C, et al, 2021)
References
- Chompunud Na Ayudhya C, et al. MRGPRX2 Activation by Rocuronium: Insights from Studies with Human Skin Mast Cells and Missense Variants. Cells. 2021, 10(1):156.
Does exposure to elevated temperatures accelerate impurity formation in Rocuronium Bromide?
Yes, Rocuronium Bromide is susceptible to temperature-related degradation. We conduct stress studies to map impurity formation, and our storage recommendations are designed to minimize this.
Is the Rocuronium Bromide packaging suitable for long-term storage in humid climates?
Absolutely. We use triple-layer, moisture-barrier foil bags with oxygen absorbers inside fiber drums specifically to protect Rocuronium Bromide from humidity during long-term storage in tropical zones.
What is the impurity profile specification for Rocuronium Bromide?
We specifically control for known process-related impurities and degradation products, ensuring they are kept to a minimum.
Can I request a customized certificate of analysis (CoA) for Rocuronium Bromide?
Yes, we can tailor the CoA format to include your specific batch number references or highlight particular pharmacopoeial tests required by your quality department.